SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com. Core Illumina Revenue of approxi ...

Partnership Overview - Illumina and NVIDIA are collaborating to combine AI advancements with multiomic data at scale, leveraging Illumina's sequencing technology and NVIDIA's AI tools to accelerate drug discovery and clinical development [1][8] - The partnership aims to integrate NVIDIA's RAPIDS™ accelerated data science software, BioNeMo™ platform, and MONAI for spatial cell imaging workflows with Illumina's Connected Analytics platform [2] - The collaboration will enable DRAGEN algorithms on NVIDIA GPUs and incorporate NVIDIA's image processing and single-cell tertiary analysis tools into Illumina's multiomics module [3] Technological Integration - Illumina's DRAGEN-powered multiomics offerings, genomics AI tools, and Connected Analytics platform have streamlined genomic data generation and analysis [10] - NVIDIA's AI and data science tools will be integrated with Illumina's sequencing and analytics platforms to drive the next generation of genomics interpretation [3] - Customers will be able to leverage NVIDIA's biology foundation models with their proprietary datasets for tasks such as cell state or gene transcription prediction [5] Industry Impact - The collaboration aims to democratize genomics for drug discovery through AI-powered insights, enabling deeper biological insights and total workflow solutions for customers [3] - The partnership is expected to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research and genomics AI development [8] - Illumina's investment in AI for genomic interpretation includes leading algorithms such as SpliceAI, PrimateAI-3D, and Emedgene xAI [10]

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® ...

SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, February 6, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call D ...

Illumina, Inc. (ILMN) has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1.3 upgrade to elevate sequencing performance and advance data quality.In addition, the new NovaSeq X 25B 100 and 200-cycle kits are now available under Illumina's brand following the company's acquisition of Fluent.ILMN Stock’s Likely Trend Following the NewsAfter yesterday’s announcement, Illumina shares edg ...

Core Product Updates - The single-flow-cell NovaSeq X Sequencing System offers high-quality flow cells and speed at a more accessible cost for labs with lower volume, shipping began in December [1] - The NovaSeq X Series software v1 3 upgrade enhances sequencing performance and data quality, with new NovaSeq X 25B 100- and 200-cycle kits also shipping in December [1] - The NovaSeq X Series is Illumina's most rapidly adopted and utilized high-throughput sequencing platform to date [1] Customer Feedback on Software Upgrade - The v1 3 software upgrade improves sequencing accuracy, yield, and reduces PhiX dependency, leading to more usable data per run [3] - Génome Québec reported a significant leap in data quality across various library types, with increased yield and optimized handling of low-diversity libraries [4] - Broad Clinical Labs observed significant high-quality data yield increases in early testing of the v1 3 update on their NovaSeq X Plus fleet [4] - University Medical Center Utrecht noted a decisive development in transitioning from whole-exome-based to whole-genome-based analysis with the v1 3 update [4] New Kits and Applications - The new 25B 100-cycle and 200-cycle kits for the NovaSeq X Series are optimized for counting applications and other assays at scale, offering shorter turnaround times and cost-effective runs [5] - The 25B kits address the evolving needs of clinical specialty labs, academic core labs, and service providers by providing flexibility in run sizes and cycle counts [5] - The NovaSeq X 25B kits are compatible with Illumina Single-Cell Prep, enabling efficient, affordable, and accurate workflows for large-scale single-cell analysis projects [9] Illumina Single-Cell Prep - Illumina Single-Cell Prep, formerly Fluent PipSeq V, is now available and shipping, offering broad compatibility across Illumina's NGS platform portfolio [6] - The technology removes barriers and limitations of current methods, enabling scalability of experiments from hundreds to millions of cells with low equipment cost and high sensitivity [6][7] - Illumina Single-Cell Prep provides streamlined bioinformatics workflows, streaming data directly into automated DRAGEN analysis in Illumina's informatics cloud solutions [9] Industry Impact and Innovation - Illumina's focus on innovation has established it as a global leader in DNA sequencing and array-based technologies, serving customers in research, clinical, and applied markets [11] - The company's products are used in life sciences, oncology, reproductive health, agriculture, and other emerging segments [11] - Early access data presented at the American Society of Human Genetics meeting highlighted the sequencing of challenging cell types, such as astrocytes and brain tissue, with innovative technology [8]

Illumina, Inc. (NASDAQ:ILMN) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra - CFO Sallilyn Schwartz - VP of Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon. I'm Vijay Kumar, a life science device analyst here at Evercore. Pleasure to have with us Illumina. We have Ankur Dhingra, CFO; and from Investor Relations, we have Salli Schwartz. Ankur, Sall ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina’s updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previo ...

Illumina, Inc. (NASDAQ:ILMN) Conference Call Summary Company Overview - **Company**: Illumina, Inc. - **Date**: November 20, 2024 - **Participants**: Ankur Dhingra (CFO), Doug Schenkel (Wolfe Research) Key Points Industry Context - **Market Dynamics**: The call discussed the implications of recent elections on NIH funding, local competition in China, and tariff impacts on the business [3][19][39]. Financial Performance and Strategy - **Revenue Growth**: Illumina aims to restore revenue growth to high-single-digit percentages over the next few years, focusing on core consumables and instrumentation [7][8]. - **Divestiture**: The company has divested GRAIL, which is expected to streamline operations and focus on core business [7]. - **Cash Flow**: Illumina has robust free cash flow and is exploring M&A opportunities while also considering share repurchases [18]. Clinical Market Insights - **High Throughput Growth**: High throughput and mid throughput sequencing activity grew 40% year-over-year, but revenue growth was impacted by pricing declines, with a noted 25% price drop during the quarter [52][56]. - **Transition to New Platforms**: The transition from older platforms to the new X platform is expected to stabilize pricing and improve revenue flow by the second half of 2025 [61]. Customer Engagement and Product Development - **Customer Collaboration**: Illumina has opened its pipeline to key customers for early access to new technologies, enhancing customer feedback and engagement [14][15]. - **Multiomics Strategy**: The company is expanding its multiomics capabilities through acquisitions and partnerships, which are expected to contribute to growth [10][16]. Challenges and Risks - **NIH Funding**: The company is monitoring NIH funding closely, noting that while direct exposure is low, any cuts could impact business indirectly [24][29]. - **China Market**: Illumina faces strong competition in China, but recent stabilization at approximately $75 million per quarter is noted. The company is making structural changes to improve its market position [39][40][41]. - **Mid Throughput Pressure**: The mid throughput segment is under pressure due to macroeconomic factors, with customers transitioning to high throughput options [77][80]. Future Outlook - **2025 Projections**: Consensus estimates suggest 4% revenue growth for 2025, with potential upside from new product launches and ongoing transitions to the X platform [83][84]. - **Market Conditions**: The company does not anticipate macroeconomic improvements in the near term, which could affect revenue trajectories [84]. Additional Insights - **Regulatory Environment**: Improvements in regulatory relationships in China are noted, allowing for increased participation in tenders and direct sales to hospitals [42][43]. - **Tariff Exposure**: Illumina's manufacturing is primarily outside of China, with minimal exposure to tariffs, allowing for flexibility in supply chain management [48][49]. This summary encapsulates the key discussions and insights from the Illumina conference call, highlighting the company's strategic direction, market challenges, and future outlook.

Illumina, Inc. (ILMN) is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2 (TSO 500 v2) to enable comprehensive genomic profiling (CGP) of tumors will be presented at the annual meeting of the Association of Molecular Pathology in Vancouver, British Columbia, on Nov. 21. One of the customers having early access to TSO 500 v2 emphasized the relevance of the assay's new features to clinical research lab ...